Compare HZO & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HZO | KALV |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 604.0M | 551.2M |
| IPO Year | 1998 | N/A |
| Metric | HZO | KALV |
|---|---|---|
| Price | $23.61 | $15.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $34.00 | $26.43 |
| AVG Volume (30 Days) | 378.2K | ★ 1.7M |
| Earning Date | 01-22-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,309,288,000.00 | $1,426,000.00 |
| Revenue This Year | $4.01 | N/A |
| Revenue Next Year | $4.20 | $234.65 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.85 | $7.30 |
| 52 Week High | $33.45 | $17.28 |
| Indicator | HZO | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 66.52 |
| Support Level | $22.49 | $13.28 |
| Resistance Level | $25.43 | $16.49 |
| Average True Range (ATR) | 1.27 | 1.03 |
| MACD | 0.15 | 0.13 |
| Stochastic Oscillator | 49.38 | 63.32 |
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.